| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 3/6 |
Hypera S.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | R$22.72 |
| 52 Week Hoogtepunt | R$37.18 |
| 52 Week Laag | R$21.21 |
| Bèta | 0.40 |
| 11 maand verandering | -15.22% |
| 3 maanden verandering | -22.72% |
| 1 Jaar Verandering | -27.99% |
| 33 jaar verandering | -21.36% |
| 5 jaar verandering | -35.86% |
| Verandering sinds IPO | 172.10% |
Recent nieuws en updates
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
Oct 03
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Jul 13Recent updates
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
Oct 03We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Jul 13Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
Jun 20Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 16Is Hypera (BVMF:HYPE3) A Risky Investment?
Feb 21Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Jan 09Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
Dec 22Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Nov 02Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Aug 27Is Hypera (BVMF:HYPE3) A Risky Investment?
Jul 21We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Apr 15With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
Feb 19We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
Jan 03Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
Oct 11Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Jul 19Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Jun 28Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Apr 14I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Mar 25Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Mar 04Rendement voor aandeelhouders
| HYPE3 | BR Pharmaceuticals | BR Markt | |
|---|---|---|---|
| 7D | -5.0% | -7.1% | -1.9% |
| 1Y | -28.0% | -6.0% | 3.3% |
Rendement versus industrie: HYPE3 underperformed the BR Pharmaceuticals industry which returned -6% over the past year.
Rendement versus markt: HYPE3 underperformed the BR Market which returned 3.3% over the past year.
Prijsvolatiliteit
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.3% |
Stabiele aandelenkoers: HYPE3 has not had significant price volatility in the past 3 months compared to the BR market.
Volatiliteit in de loop van de tijd: HYPE3's weekly volatility (6%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 10,301 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. is een farmaceutisch bedrijf in Brazilië. Het biedt producten op recept aan onder de merknamen Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex - A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, en velunid merken. Het bedrijf levert ook zonbeschermende en vochtinbrengende huidverzorgingsproducten onder de merknamen Mantecorp Skincare; soortgelijke producten onder de merknamen Doralgina, Dropy D, Equilibrisse, Balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum en Torsilax; en receptvrije geneesmiddelen onder de merknamen Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil en Neosaldina, evenals soortgelijke en generieke geneesmiddelen onder het merk Neo Química.
Hypera S.A. Samenvatting
| HYPE3 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | R$14.36b |
| Inkomsten(TTM) | R$1.69b |
| Inkomsten(TTM) | R$8.00b |
8.5x
Koers/Winstverhouding1.8x
P/S-verhoudingIs HYPE3 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HYPE3 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | R$8.00b |
| Kosten van inkomsten | R$3.05b |
| Brutowinst | R$4.95b |
| Overige uitgaven | R$3.26b |
| Inkomsten | R$1.69b |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
Nov 13, 2024
| Winst per aandeel (EPS) | 2.68 |
| Brutomarge | 61.86% |
| Nettowinstmarge | 21.17% |
| Schuld/Eigen Vermogen Verhouding | 84.8% |
Hoe presteerde HYPE3 op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
5.4%
Huidig dividendrendement30%
UitbetalingsratioBetaalt HYPE3 een betrouwbaar dividend?
Zie HYPE3 dividendgeschiedenis en benchmarks| Hypera dividenddata | |
|---|---|
| Ex Dividend Datum | Sep 28 2023 |
| Betaaldatum dividend | Dec 31 2024 |
| Dagen tot Ex-dividend | 404 days |
| Dagen tot dividendbetaaldatum | 56 days |
Betaalt HYPE3 een betrouwbaar dividend?
Zie HYPE3 dividendgeschiedenis en benchmarks